Discover: TRUQAP + Fulvestrant Combination Mechanism of Action

TRUQAP - the first and only AKT pathway inhibitor indicated in one or more alterations of PIK3CA/AKT1/PTEN in HR-positive, HER2-negative locally advanced or metastatic breast cancer, in combination with fulvestrant, a nonagonist estrogen receptor antagonist.^2,9,10*

Adapted from the TRUQAP and Faslodex Product Monographs^1,10†

In tumours, AKT activation occurs as a result of upstream activation by other signalling pathways and also through genetic alterations in AKT1 phosphatase, PTEN and/or PIK3CA.^1†

AKT

PI3K/AKT/PTEN pathway¹

AKT=serine/threonine protein kinases; AKT1=serine/threonine protein kinase 1; ER=estrogen receptor; PI3K=phosphoinositide 3-kinase; PTEN=phosphatase and tensin homolog.

* Comparative clinical significance has not been established.

† Clinical significance has not been established.

Learn about the safety profile of TRUQAP

Learn about TRUQAP dosing and administration

Discover: TRUQAP + Fulvestrant Combination Mechanism of Action

TRUQAP - the first and only AKT pathway inhibitor indicated in one or more alterations of PIK3CA/AKT1/PTEN in HR-positive, HER2-negative locally advanced or metastatic breast cancer, in combination with fulvestrant, a nonagonist estrogen receptor antagonist.2,9,10*

TRUQAP - the first and only AKT pathway inhibitor indicated in one or more alterations of PIK3CA/AKT1/PTEN in HR-positive, HER2-negative locally advanced or metastatic breast cancer, in combination with fulvestrant, a nonagonist estrogen receptor antagonist.^2,9,10*